FR3116216B1 - Procédé de préparation de nanoparticules - Google Patents

Procédé de préparation de nanoparticules Download PDF

Info

Publication number
FR3116216B1
FR3116216B1 FR2011904A FR2011904A FR3116216B1 FR 3116216 B1 FR3116216 B1 FR 3116216B1 FR 2011904 A FR2011904 A FR 2011904A FR 2011904 A FR2011904 A FR 2011904A FR 3116216 B1 FR3116216 B1 FR 3116216B1
Authority
FR
France
Prior art keywords
preparing nanoparticles
nanoparticles
preparing
tumors
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2011904A
Other languages
English (en)
Other versions
FR3116216A1 (fr
Inventor
Olivier Tillement
François Lux
Fabien Rossetti
Paul Rocchi
Tristan Doussineau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
NH Theraguix SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
NH Theraguix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2011904A priority Critical patent/FR3116216B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 UCBL, NH Theraguix SA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN202180077639.8A priority patent/CN116472067A/zh
Priority to CA3201459A priority patent/CA3201459A1/fr
Priority to TW110143272A priority patent/TW202231300A/zh
Priority to PCT/FR2021/052041 priority patent/WO2022106788A1/fr
Priority to US18/253,586 priority patent/US20230405154A1/en
Priority to EP21824616.3A priority patent/EP4247435A1/fr
Priority to JP2023530233A priority patent/JP2023550429A/ja
Publication of FR3116216A1 publication Critical patent/FR3116216A1/fr
Application granted granted Critical
Publication of FR3116216B1 publication Critical patent/FR3116216B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Colloid Chemistry (AREA)

Abstract

La présente divulgation porte sur des nanoparticules et leurs utilisations dans le domaine de la médecine, en particulier pour le traitement de tumeurs.
FR2011904A 2020-11-19 2020-11-19 Procédé de préparation de nanoparticules Active FR3116216B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2011904A FR3116216B1 (fr) 2020-11-19 2020-11-19 Procédé de préparation de nanoparticules
CA3201459A CA3201459A1 (fr) 2020-11-19 2021-11-19 Procede de preparation de nanoparticules
TW110143272A TW202231300A (zh) 2020-11-19 2021-11-19 製備奈米粒子之膠體溶液的方法
PCT/FR2021/052041 WO2022106788A1 (fr) 2020-11-19 2021-11-19 Procédé de préparation de nanoparticules
CN202180077639.8A CN116472067A (zh) 2020-11-19 2021-11-19 用于制备纳米颗粒的方法
US18/253,586 US20230405154A1 (en) 2020-11-19 2021-11-19 Method for preparing nanoparticles
EP21824616.3A EP4247435A1 (fr) 2020-11-19 2021-11-19 Procédé de préparation de nanoparticules
JP2023530233A JP2023550429A (ja) 2020-11-19 2021-11-19 ナノ粒子の調製方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2011904A FR3116216B1 (fr) 2020-11-19 2020-11-19 Procédé de préparation de nanoparticules
FR2011904 2020-11-19

Publications (2)

Publication Number Publication Date
FR3116216A1 FR3116216A1 (fr) 2022-05-20
FR3116216B1 true FR3116216B1 (fr) 2023-10-27

Family

ID=74592123

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2011904A Active FR3116216B1 (fr) 2020-11-19 2020-11-19 Procédé de préparation de nanoparticules

Country Status (8)

Country Link
US (1) US20230405154A1 (fr)
EP (1) EP4247435A1 (fr)
JP (1) JP2023550429A (fr)
CN (1) CN116472067A (fr)
CA (1) CA3201459A1 (fr)
FR (1) FR3116216B1 (fr)
TW (1) TW202231300A (fr)
WO (1) WO2022106788A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024013272A1 (fr) * 2022-07-13 2024-01-18 Universite De Montpellier Thérapie combinée avec des nanoparticules et des produits radiopharmaceutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
EP3551231A4 (fr) * 2016-12-08 2020-08-12 The Brigham and Women's Hospital, Inc. Nanoparticules de bismuth-gadolinium
JP7225126B2 (ja) 2017-06-09 2023-02-20 エヌアッシュ テラギ シリカナノ粒子の合成方法
EP3424533A1 (fr) 2017-07-05 2019-01-09 Nh Theraguix Procédés de traitement de la dépendance

Also Published As

Publication number Publication date
TW202231300A (zh) 2022-08-16
US20230405154A1 (en) 2023-12-21
CA3201459A1 (fr) 2022-05-27
CN116472067A (zh) 2023-07-21
WO2022106788A1 (fr) 2022-05-27
FR3116216A1 (fr) 2022-05-20
JP2023550429A (ja) 2023-12-01
EP4247435A1 (fr) 2023-09-27

Similar Documents

Publication Publication Date Title
MA44851A (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
FR3116216B1 (fr) Procédé de préparation de nanoparticules
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA42399B1 (fr) Composés inhibiteurs de la voie de signalisation de notch
RU2014141365A (ru) Способ введения противоопухолевого агента
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MA38925B1 (fr) Dérivés de phénylalanine substitués
MX2022011499A (es) Composiciones y metodos para tratar la distrofia muscular facioescapulohumeral.
EP4389146A3 (fr) Thérapie immunoconjuguée par tnf-a pour le traitement de tumeurs cérébrales
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX2021012543A (es) Compuestos de indoles quirales y su uso.
FR3046728B1 (fr) Nouvelles nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations.
MX2023003725A (es) Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación.
MX2022008632A (es) Agente de union a ccr5 para el tratamiento de cancer metastasico positivo para ccr5.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
TN2014000371A1 (fr) Dérivés macrocycliques pour le traitement de maladies prolifératives
EA201001640A1 (ru) Фармацевтическая антибактериальная композиция на основе наночастиц циклодекстрина, содержащих антибиотик из группы рифамицинов, способ ее получения и способы лечения
FR3108031B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220520

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4